Patritumab

Patritumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.[1]

Patritumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII

Clinical trials

It is in a phase 2 clinical trial for squamous cell cancer of the head and neck.[2]

It is to be included in a new arm of the I-SPY 2 breast cancer trial.[3]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.